AI Generated Image
4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain
PR Newswire • • business
Key Points:
- Eli Lilly and Company has acquired 4E Therapeutics, an Austin-based neuroscience company developing next-generation, non-opioid treatments for chronic pain.
- 4E's pipeline focuses on orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons to provide pain relief without central nervous system side effects.
- The lead compound, 4ET1103, is the first MNK inhibitor for pain to reach human clinical trials, showing a favorable safety profile in Phase 1 studies.
- 4E's founders emphasized Lilly's global development and commercial capabilities as key to advancing their innovative therapies to patients suffering from chronic pain.
- Financial terms of the acquisition were not disclosed, with Aquilo Partners LP advising 4E and Wilson Sonsini Goodrich & Rosati LLP providing legal counsel.
